Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
You may also be interested in...
Ipsen Sees First Mover Advantage In EU For Cabometyx In Liver Cancer
Ipsen CSO says CHMP recommendation for TKI Cabometyx should give it first mover advantage globally in liver cancer.
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.
Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.